We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan’s Mirapex Antitrust Lawsuit Is Subject of Boehringer Motion
Mylan’s Mirapex Antitrust Lawsuit Is Subject of Boehringer Motion
January 5, 2010
Responding to a Mylan Pharmaceuticals antitrust lawsuit, Boehringer Ingelheim has filed a motion to dismiss the case in which Mylan contends the drugmaker
took unlawful action to protect an invalid patent on its Parkinson’s disease drug Mirapex.